#28Health Care· Health Care Equipment

DXCMSell

Dexcom

$61.63USD

Composite Score65.0Strong

<−99

Margin of safety<−99%Expensive

Fair value$21.16

Target$63.43

Loss chance52%

Price (1y)

Loading price history…

Recent regulatory events

Auditor change (8-K Item 4.01)AnnotateView filing

Latest 8-K: 2025-03-25

Fair price check

6 different valuation methods each estimate what DXCM should be worth, then we compare to today's price.

Heavily overvalued

Models suggest DXCM is far above estimated fair value

Today's price

$61.63

Median fair price

$21.16

-66% vs today

Of 6 methods:2 say fair4 say pricey

P/E multiplesFair
thinks it's fairly priced — estimates $63.43, about 3% above today
EV/EBITDAFair
thinks it's fairly priced — estimates $60.38, about 2% below today
P/B multiplesOvervalued
thinks it's expensive — estimates $22.28, about 64% below today
DCF (2-stage)Overvalued
thinks it's expensive — estimates $20.04, about 67% below today
Graham (defensive)Overvalued
thinks it's expensive — estimates $16.38, about 73% below today
Residual IncomeOvervalued
thinks it's expensive — estimates $15.88, about 74% below today

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair

$21.16

Margin of safety

< −99%

Max (ex-outliers)

$63.43

Tangible BVPS

$7.44

Method	Value
Graham (defensive)	$16.38
P/E multiples(vs sub industry peers)	$63.43
P/B multiples(vs sub industry peers)	$22.28
EV/EBITDA(vs sub industry peers)	$60.38
Residual Income	$15.88
DCF (2-stage)	$20.04

Median of all applicable methods (current price $61.63). Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Pillar breakdown

8 dimensions, each scored 0–100 against the universe

Health Care median (n=59)

Quality
Profit margins & asset efficiency
88
Strong
Value
Price vs fundamentals
38
Weak
Growth
Revenue & earnings trajectory
94
Strong
Momentum
Recent price strength
23
Poor
Health
Balance sheet & solvency
88
Strong
Profitability
ROE, ROA, ROIC
73
Strong
Technical
Trend & volatility signals
73
Strong
Risk
Volatility & drawdown profile
18
Poor

0305070100

Strong (70+)Decent (50–70)Weak (30–50)Poor (<30)

Pillars not shown: Sentiment, ML (Phase 5+).

Raw fundamentals (SEC EDGAR)

Metric	Value
Market cap	$23.78B
Revenue (TTM)	$4.82B
Net income (TTM)	$930.40M
Operating cash flow (TTM)	$1.78B
CapEx (TTM)	$353.10M
Free cash flow (TTM)CFO − CapEx	$1.43B
Total assets	$6.63B
Total liabilities	$3.68B
Stockholders' equity	$2.96B
Cash & equivalents	$1.12B
Shares outstanding	385.87M
EPS (basic)	$0.52
EPS (diluted)	$0.51
P/E ratio (TTM)	25.56

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date: 2026-04-30
Latest period end: 2026-04-23
Filing lag: 16 days
Missing metrics: 3(dividends_paid, accounts_payable, short_term_debt)

Phase 3c — composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars land in Phases 5-6; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.